APOBEC Mutagenesis in Cancer Development and Susceptibility

Area of Science:

• Biochemistry
• Genetics
• Oncology

Background:

• APOBEC (apolipoprotein B mRNA editing catalytic polypeptide-like) cytosine deaminases are significant mutagens in human cancers, implicated in over 50% of malignancies.
• APOBEC-driven mutagenesis contributes to tumor heterogeneity, cellular evolution, and patient responses to cancer therapies.

Purpose of the Study:

• To review and synthesize current evidence on the role of APOBEC mutagenesis in cancer initiation and progression.
• To identify knowledge gaps and propose future research directions for understanding APOBEC's contribution to carcinogenesis.

Main Methods:

• Analysis of existing literature on germline polymorphisms in APOBEC genes and their association with cancer risk.
• Examination of APOBEC activity through sequencing data from human malignant and non-malignant tissues.
• Inclusion of findings from in vivo studies investigating APOBEC mutagenesis in cancer development.

Main Results:

• APOBEC enzymes are established drivers of mutations across numerous cancer types.
• Evidence links APOBEC activity to key cancer hallmarks, including evolution and therapy resistance.
• The specific contribution of APOBEC mutagenesis to initial cancer susceptibility and malignant transformation remains incompletely understood.

Conclusions:

• APOBEC mutagenesis is a critical factor in cancer progression and evolution.
• Further investigation into germline variations, tissue-specific APOBEC activity, and in vivo models is essential.
• Elucidating APOBEC's role in early carcinogenesis is crucial for developing novel cancer prevention and treatment strategies.